Condensed Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Operating activities:
Net income (loss)	$ 5,757	$ 16,062
Adjustments to reconcile net income to net cash provided by operating activities:
Non-cash expense related to stock-based compensation	3,199	2,130
Depreciation and amortization	3,246	1,911
Intangible asset impairment	42,728
Change in fair value of contingent consideration	(14,860)	(1,423)
Deferred taxes, net	(7,052)	(871)
Other long-term liabilities	(199)	(456)
Changes in operating assets and liabilities:
Accounts receivable, net	5,252	(12,264)
Inventories	2,690	(2,017)
Prepaid expenses and other assets	565	604
Accounts payable	(3,703)	(2,279)
Accrued and other current liabilities	3,329	2,713
Net cash provided by operating activities	40,952	4,110
Investing activities:
Acquisition of NovaMed, net of cash acquired		(21,257)
Purchases of available-for-sale investments		(1,580)
Proceeds from the sale or maturities of available-for-sale investments		3,725
Purchases of property and equipment	(1,036)	(558)
Net cash used in investing activities	(1,036)	(19,670)
Financing activities:
Repurchase of common stock	(18,465)
Repayment of line of credit	(2,500)
Increase in restricted cash related to line of credit	(2,300)
Proceeds from issuances of common stock	3,250	6,019
Net cash (used in) provided by financing activities	(20,015)	6,019
Effect of exchange rate changes on cash and cash equivalents	(12)	145
Net increase (decrease) in cash and cash equivalents	19,889	(9,396)
Cash and cash equivalents, beginning of period	66,654	53,017
Cash and cash equivalents, end of period	86,543	43,621
Supplemental disclosure of cash flow information:
Income taxes paid related to foreign operations	1,178	767
Interest and unused line fees paid related to line of credit	$ 125	$ 126